Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06780449 · ClinicalTrials.gov registry record · Phase 3

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.

Active
Registry status
Phase 3
Development phase
400
Enrollment target
20
Study locations

NCT06780449 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 400 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06780449, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
400 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by chance and is not known by participants or the study doctor. In the extension phase participants will get either CagriSema or slowly reduce participants dose of CagriSema if participants had CagriSema in the main phase. Which treatment participants get is decided by chance and is not known by participants or the study doctor in both phases. If participants had "dummy medicine" in the main phase, participants will get CagriSema in the extension phase. Like all medicines, the study medicine may have side effects.

Conditions Studied

Obesity

Interventions

  • DRUG Semaglutide
  • DRUG Cagrilintide
  • DRUG Placebo cagrilintide
  • DRUG Placebo semaglutide

Study Locations (20)

Other

  • Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie - Brussels
  • UZA - UZ Antwerpen - Department of Endocrinology - Edegem
  • UZ Leuven - Endocrinology - Leuven
  • CHU Helora - Hôpital de Mons - Site Constantinople - Mons
  • Alpha Recherche Clinique - Lebourgneuf - Québec
  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus - Aarhus
  • Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden - Esbjerg

California

  • Valley Clinical Trials - Covina
  • Diablo Clinical Research, Inc. - Walnut Creek

Connecticut

  • Yale University School Of Medicine - New Haven

Hawaii

  • East West Medical Research Institute_Honolulu - Honolulu

Kentucky

  • L-MARC Research Center - Louisville

Missouri

  • StudyMetrix Research LLC - City of Saint Peters

South Carolina

  • Spartanburg Medical Research - Spartanburg

Tennessee

  • Holston Medical Group_Bristol - Bristol

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2025-02-10
Est. Completion 2028-10-31
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06780449

The ClinicalTrials.gov registry entry for NCT06780449 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (51% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide is the first listed.

NCT06780449 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06780449 about?

NCT06780449 is a clinical study titled "A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity". This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 year...

What is the current status of trial NCT06780449?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2025-02-10. Estimated completion is 2028-10-31.

What conditions does trial NCT06780449 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06780449?

The interventions under investigation include: Semaglutide (DRUG), Cagrilintide (DRUG), Placebo cagrilintide (DRUG), Placebo semaglutide (DRUG).

Who is sponsoring clinical trial NCT06780449?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06780449 being conducted?

This trial has 20 study locations across California, Connecticut, Hawaii, Kentucky, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.